MX2015015355A - Tratamiento de enfermedades miopaticas y neurodegenerativas por agregacion de proteina mediante administracion parenteral. - Google Patents

Tratamiento de enfermedades miopaticas y neurodegenerativas por agregacion de proteina mediante administracion parenteral.

Info

Publication number
MX2015015355A
MX2015015355A MX2015015355A MX2015015355A MX2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A MX 2015015355 A MX2015015355 A MX 2015015355A
Authority
MX
Mexico
Prior art keywords
trehalose
treatment
protein aggregation
myopathic
parenteral administration
Prior art date
Application number
MX2015015355A
Other languages
English (en)
Spanish (es)
Inventor
Dalia Megiddo
Original Assignee
Bio Blast Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd filed Critical Bio Blast Pharma Ltd
Publication of MX2015015355A publication Critical patent/MX2015015355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015015355A 2013-05-07 2014-05-07 Tratamiento de enfermedades miopaticas y neurodegenerativas por agregacion de proteina mediante administracion parenteral. MX2015015355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Publications (1)

Publication Number Publication Date
MX2015015355A true MX2015015355A (es) 2016-07-18

Family

ID=51022384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015355A MX2015015355A (es) 2013-05-07 2014-05-07 Tratamiento de enfermedades miopaticas y neurodegenerativas por agregacion de proteina mediante administracion parenteral.

Country Status (14)

Country Link
US (5) US10493023B2 (cg-RX-API-DMAC7.html)
EP (2) EP2994145B1 (cg-RX-API-DMAC7.html)
JP (5) JP6837835B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160009617A (cg-RX-API-DMAC7.html)
AU (5) AU2014264228A1 (cg-RX-API-DMAC7.html)
CA (3) CA3239805A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150637A (cg-RX-API-DMAC7.html)
EA (1) EA201501054A1 (cg-RX-API-DMAC7.html)
IL (1) IL241757B (cg-RX-API-DMAC7.html)
MD (1) MD20150120A2 (cg-RX-API-DMAC7.html)
MX (1) MX2015015355A (cg-RX-API-DMAC7.html)
PE (1) PE20160012A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201509030TA (cg-RX-API-DMAC7.html)
WO (1) WO2014181333A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014181333A2 (en) 2013-05-07 2014-11-13 Bio Blast Pharma Ltd. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US9084720B2 (en) * 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
CA3012502A1 (en) * 2016-02-08 2017-08-17 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
WO2019143685A1 (en) 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
CA3150309A1 (en) 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof
EP4741013A3 (en) * 2020-02-13 2026-08-05 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent
WO2022013940A1 (ja) 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
CN116966192A (zh) * 2022-09-26 2023-10-31 西安文理学院 海藻糖在制备sca3疾病治疗药物中的应用
AU2023403437A1 (en) * 2022-11-30 2025-06-19 GLD Debt Acquisition 2025-1, Inc. Trehalose for treating huntington's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS4950521U (cg-RX-API-DMAC7.html) 1972-08-14 1974-05-02
JPS516109B2 (cg-RX-API-DMAC7.html) 1972-12-28 1976-02-25
JPS557829Y2 (cg-RX-API-DMAC7.html) 1974-07-01 1980-02-21
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
AU1172097A (en) 1995-12-27 1997-07-28 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
EP1600143B1 (en) 2003-02-13 2019-07-10 Hayashibara Co., Ltd. SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
EP1888095A4 (en) 2005-05-13 2009-08-26 Whitehead Biomedical Inst MODULATORS OF ALPHA-SYNUCLEIN INDUCED TOXICITY
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
CN102266274B (zh) 2005-08-11 2016-05-18 株式会社林原 胶原产生增强剂及其用途
EP1958612B1 (en) 2005-11-30 2014-07-02 The Nisshin OilliO Group, Ltd. Trehalose fatty acid ester composition
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
CN101443344B (zh) 2006-03-27 2012-08-29 大塚化学株式会社 海藻糖化合物及含有该化合物的药物
CN101091713A (zh) * 2006-06-19 2007-12-26 深圳市牌牌科技有限公司 预防和治疗神经损伤类疾病雷公藤红素胶囊及其制备方法和用法
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
JP5258582B2 (ja) 2007-01-31 2013-08-07 株式会社糖鎖工学研究所 トレハロース化合物、その製造方法、及び該化合物を含有する免疫賦活剤
EP2198869B1 (en) * 2007-02-23 2015-09-16 Next 21 K.K. Trehalose for the treatment or prevention of vasospasm
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
EA201070544A1 (ru) * 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
US20110142799A1 (en) * 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
WO2010050178A1 (ja) 2008-10-31 2010-05-06 大塚化学株式会社 トレハロース化合物、その製造方法、及び該化合物を含有する医薬
WO2010056804A1 (en) * 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
EP3689346B1 (en) 2008-12-10 2024-01-24 WisTa Laboratories Ltd. 3,6-disubstituted xanthylium salts for treating tauopathies
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
WO2011108762A1 (ja) 2010-03-05 2011-09-09 株式会社林原生物化学研究所 インスリン抵抗性の予防及び/又は改善剤
KR20130043165A (ko) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
EP2637652A2 (en) * 2010-11-10 2013-09-18 Katholieke Universiteit Leuven Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
ES2664844T3 (es) 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
WO2014181333A2 (en) 2013-05-07 2014-11-13 Bio Blast Pharma Ltd. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
EP4026545A1 (en) 2014-11-19 2022-07-13 Rush University Medical Center Compositions and methods for treating lysosomal disorders
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof
WO2017136533A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
CA3150309A1 (en) 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof

Also Published As

Publication number Publication date
CA2911399A1 (en) 2014-11-13
AU2020277197A1 (en) 2020-12-24
US20190374463A1 (en) 2019-12-12
AU2023200303A1 (en) 2023-02-23
AU2014264228A1 (en) 2015-11-12
JP2021152032A (ja) 2021-09-30
EP4218769A3 (en) 2023-10-18
JP2019142907A (ja) 2019-08-29
US12239733B2 (en) 2025-03-04
US20240009113A1 (en) 2024-01-11
CA2911399C (en) 2024-09-10
EP4218769A2 (en) 2023-08-02
US10493023B2 (en) 2019-12-03
MD20150120A2 (ro) 2016-03-31
KR20160009617A (ko) 2016-01-26
AU2019204513B2 (en) 2020-09-10
JP2025087858A (ja) 2025-06-10
WO2014181333A3 (en) 2015-01-08
WO2014181333A2 (en) 2014-11-13
JP2016518403A (ja) 2016-06-23
JP2023040211A (ja) 2023-03-22
PE20160012A1 (es) 2016-02-14
CA3311794A1 (en) 2026-06-21
US10869831B2 (en) 2020-12-22
CA3239805A1 (en) 2014-11-13
EA201501054A1 (ru) 2016-04-29
US20160120798A1 (en) 2016-05-05
AU2019204513A1 (en) 2019-07-18
US20220117883A1 (en) 2022-04-21
EP2994145B1 (en) 2023-01-04
JP6837835B2 (ja) 2021-03-03
SG11201509030TA (en) 2015-11-27
US20260014072A1 (en) 2026-01-15
IL241757B (en) 2020-05-31
HK1217300A1 (en) 2017-01-06
EP2994145A2 (en) 2016-03-16
AU2025201824A1 (en) 2025-04-03
CR20150637A (es) 2016-04-05

Similar Documents

Publication Publication Date Title
WO2014181333A3 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
MX2017005875A (es) Metodos para tratar enfermedades oculares.
BR112015027297A8 (pt) administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
BR112015027682A2 (pt) Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
NZ714684A (en) Stable oral solutions for combined api
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
EP2981258B8 (en) Pharmaceutical formulations for subcutaneous administration of furosemide
MX2015013091A (es) Metodos mejorados de uso para secretoglobinas humanas recombinantes.
MX382476B (es) Dispersiones solidas de bendamustina e infusion continua.
EA201890788A1 (ru) Препараты оланзапина с замедленным высвобождением
IL280952A (en) Methods and drug compounds for the treatment of ophthalmic diseases
GB2558494B (en) Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
WO2014107737A3 (en) Local delivery of il-17 inhibitors for treating ocular disease
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX2016010087A (es) Filtros para equipos de infusion.
BR112015013223A2 (pt) composição farmacêutica
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
MX2015016678A (es) Formulaciones farmaceuticas que comprenden agomelatina en forma de cocristal de agomelatina con un acido organico.
AR102494A1 (es) Métodos para tratar enfermedades oculares